Your browser doesn't support JavaScript. Please upgrade to a modern browser or enable JavaScript in your existing browser.
Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
www.ahrq.gov


Figure 1. Analytic Framework

Analytic Framework outlines patient population, interventions, and health outcomes focused on in this report.  Go to Key Questions below for details.

Key Questions:

1. Do risk assessment and BRCA mutation testing lead to a reduction in the incidence of breast and ovarian cancer and cause-specific or all-cause mortality?
2A. How well does risk assessment for cancer susceptibility by a clinician in a primary care setting select candidates for BRCA mutation testing?
2B. What are the benefits of genetic counseling before testing?
2C. Among women with family histories predicting an average, moderate, or high risk for a deleterious mutation, how well does BRCA mutation testing predict risk for breast and ovarian cancer?
3. What are the adverse effects of risk assessment, genetic counseling, and testing?
4. How well do interventions reduce the incidence and mortality of breast and ovarian cancer in women identified as high risk by history, positive genetic test results, or both?
5. What are the adverse effects of interventions?

Return to Document

 

AHRQ Advancing Excellence in Health Care